섹션 설정
New Drug Candidate for Dry Eye syndrome
RCI 001
RCI001
Candidate substance for dry eye treatment with strong anti-inflammatory action
▪ Patents for domestic use 10-1816277, U.S. patent application
10-675294
▪ Domestic technology transfer: Hanlim Pharmaceutical Co., Ltd.
▪ Overseas L/O goal after Phase 2 clinical trials
▪ South Korea MFDS Phase 1 clinical trials: 2023 1H
▪ US FDA Phase 2 clinical trials: 2023 2H